American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Neuropsychopharmacology (1997) 17 317-325.

Effects of Clozapine on Plasma Catecholamines and Relation to Treatment Response in Schizophrenia: A Within-Subject Comparison with Haloperidol

Alan S Brown MD 1, George Gewirtz MD1, Jill Harkavy-Friedman Ph.D1, Thomas Cooper MA2, Gildas Brébion Ph.D1, Xavier F Amador Ph.D1, Dolores Malaspina MD1 and Jack M Gorman MD1
1From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, New York, U.S.A
2Nathan Kline Institute, Orangeburg, New York

Correspondence: Dr Alan S Brown, New York State Psychiatric Institute, 722 W. 168th Street, Unit 2, New York, NY 10032

ABSTRACT

We conducted a within-subject comparison of the effects of clozapine and haloperidol on plasma levels of neurotransmitters and metabolites, and related changes in specific plasma neurochemicals with clozapine response. The subjects were 14 inpatients with schizophrenia or schzoaffective disorder, who were refractory to haloperidol and at least one other typical antipsychotic medication. Subjects underwent, in the following order: a 6-week "fixed, flexible dose" haloperidol trial, followed by a 2¾4 week medication-free phase, and a 6-week clozapine trial. Plasma levels of norepinephrine (NE), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), and objective clinical ratings of total, positive, negative, and depressive symptoms were obtained at the end of each phase. As expected, we found a substantial increase of plasma NE with clozapine but not with haloperidol. However, the increase in NE was not associated with improvement in total or positive symptomatology. There was some evidence for an association between improvement in negative symptoms and increased HVA on clozapine, as well as diminished HVA during the medication-free phase. The implications of these data for understanding the mechanisms of action of clozapine are discussed. Ó 1997 American College of Neuropsyphopharmacology

Keywords: Clozapine; Schizophrenia; Norepinephrine; Homovanillic acid; Symptomatology
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1997 by the American College of Neuropsychopharmacology